AR082049A1 - Formulaciones liquidas de rupatadina fumarato - Google Patents
Formulaciones liquidas de rupatadina fumaratoInfo
- Publication number
- AR082049A1 AR082049A1 ARP110102329A ARP110102329A AR082049A1 AR 082049 A1 AR082049 A1 AR 082049A1 AR P110102329 A ARP110102329 A AR P110102329A AR P110102329 A ARP110102329 A AR P110102329A AR 082049 A1 AR082049 A1 AR 082049A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- composition according
- rupatadine
- macrogol
- cosolvents
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 12
- 239000000203 mixture Substances 0.000 abstract 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 9
- JYBLCDXVHQWMSU-WLHGVMLRSA-N (e)-but-2-enedioic acid;8-chloro-11-[1-[(5-methylpyridin-3-yl)methyl]piperidin-4-ylidene]-5,6-dihydrobenzo[1,2]cyclohepta[2,4-b]pyridine Chemical compound OC(=O)\C=C\C(O)=O.CC1=CN=CC(CN2CCC(CC2)=C2C3=NC=CC=C3CCC3=CC(Cl)=CC=C32)=C1 JYBLCDXVHQWMSU-WLHGVMLRSA-N 0.000 abstract 7
- 239000006184 cosolvent Substances 0.000 abstract 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 abstract 3
- 229910000397 disodium phosphate Inorganic materials 0.000 abstract 3
- 235000019800 disodium phosphate Nutrition 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- 229960003511 macrogol Drugs 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 2
- WUZYKBABMWJHDL-UHFFFAOYSA-N rupatadine Chemical compound CC1=CN=CC(CN2CCC(CC2)=C2C3=NC=CC=C3CCC3=CC(Cl)=CC=C32)=C1 WUZYKBABMWJHDL-UHFFFAOYSA-N 0.000 abstract 2
- 229960005328 rupatadine Drugs 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 abstract 1
- 239000005695 Ammonium acetate Substances 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 abstract 1
- 239000007836 KH2PO4 Substances 0.000 abstract 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000024780 Urticaria Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 201000010435 allergic urticaria Diseases 0.000 abstract 1
- 229940043376 ammonium acetate Drugs 0.000 abstract 1
- 235000019257 ammonium acetate Nutrition 0.000 abstract 1
- 239000013011 aqueous formulation Substances 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 239000007979 citrate buffer Substances 0.000 abstract 1
- 229940097362 cyclodextrins Drugs 0.000 abstract 1
- 239000000975 dye Substances 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 238000004128 high performance liquid chromatography Methods 0.000 abstract 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 abstract 1
- 235000019796 monopotassium phosphate Nutrition 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 abstract 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 abstract 1
- 229940037001 sodium edetate Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Formulaciones acuosas líquidas de rupatadina fumarato libres de ciclodextrinas útiles para el tratamiento de la rinitis alérgica y la urticaria. Dichas formulaciones comprenden rupatadina fumarato, uno o más cosolventes y uno o más reguladores del pH donde la composición tiene un pH entre 4 y 6.5.Reivindicación 1: Una composición farmacéutica líquida acuosa libre de ciclodextrinas caracterizada porque comprende: rupatadina fumarato, uno o más cosolventes, uno o más agentes reguladores del pH, donde la composición tiene un pH entre 4 y 6.5. Reivindicación 3: Una composición farmacéutica según cualquiera de las reivindicaciones anteriores caracterizada porque la cantidad total de cosolvente(s) es del 5 al 50% de la formulación. Reivindicación 5: Una composición farmacéutica según cualquiera de las reivindicaciones anteriores caracterizada porque la composición comprende uno o más cosolventes seleccionados del grupo que consiste en etanol, isopropanol, propilenglicol, glicerina, macrogol 300, macrogol 400, dimetilacetamida y pirrolidona. Reivindicación 6: Una composición farmacéutica según la reivindicación 5 caracterizada porque la composición comprende uno o más cosolventes seleccionados del grupo que consiste en etanol, propilenglicol, macrogol 300 y macrogol 400. Reivindicación 8: Una composición farmacéutica según la reivindicación 7 caracterizada porque el cosolvente se selecciona del grupo que consiste en propilenglicol y macrogol 400. Reivindicación 11: Una composición farmacéutica según la reivindicación 10 caracterizada porque el uno o más agentes reguladores del pH se seleccionan del grupo que consiste en tampones fosfato, Na2HPO4/ácido cítrico, tampón citrato, ácido acético/acetato sádico y acetato amónico/edetato sódico. Reivindicación 12: Una composición farmacéutica según la reivindicación 11 caracterizada porque la composición comprende solo un tampón seleccionado del grupo que consiste en Na2HPO4/ácido cítrico y Na2HPO4/KH2PO4. Reivindicación 14: Una composición farmacéutica según la reivindicación 13 caracterizada porque la composición comprende solo un regulador del pH que es NaOH. Reivindicación 21: Una composición farmacéutica según cualquiera de las reivindicaciones anteriores caracterizada porque comprende rupatadina fumarato a una concentración de 0,5 a 1,5 g (rupatadina)/L. Reivindicación 22: Una composición farmacéutica según cualquiera de las reivindicaciones anteriores caracterizada porque comprende rupatadina fumarato a una concentración de 1 g (rupatadina)/L. Reivindicación 23: Una composición farmacéutica según cualquiera de las reivindicaciones anteriores caracterizada porque comprende además uno o más de los siguientes excipientes: uno o más colorantes, uno o más aromatizantes, uno o más agentes conservantes. Reivindicación 24: Un proceso para la preparación de una composición farmacéutica según cualquiera de las reivindicaciones 1 a 23 caracterizado porque comprende: a) disolver la rupatadina fumarato en uno o más cosolventes para obtener una primera solución, y b) añadir agua y uno o más agentes reguladores del pH a la primera solución. Reivindicación 33: Un método para determinar la pureza de una composición que comprende rupatadina fumarato, caracterizado porque comprende determinar la concentración del compuesto de fórmula (1) en dicha composición usando el compuesto de fórmula (1) como patrón en un método de HPLC.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382184 | 2010-06-30 | ||
| US36499210P | 2010-07-16 | 2010-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082049A1 true AR082049A1 (es) | 2012-11-07 |
Family
ID=42813412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102329A AR082049A1 (es) | 2010-06-30 | 2011-06-30 | Formulaciones liquidas de rupatadina fumarato |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP2402012B1 (es) |
| JP (1) | JP5475929B2 (es) |
| CN (1) | CN103108635B (es) |
| AR (1) | AR082049A1 (es) |
| BR (1) | BR112012029009B1 (es) |
| CA (1) | CA2798028A1 (es) |
| EA (1) | EA201291151A1 (es) |
| ES (1) | ES2401318T3 (es) |
| MX (1) | MX2012013077A (es) |
| MY (1) | MY161101A (es) |
| PH (1) | PH12012502260A1 (es) |
| PL (1) | PL2402012T3 (es) |
| PT (1) | PT2402012E (es) |
| SG (1) | SG186270A1 (es) |
| SI (1) | SI2402012T1 (es) |
| TW (1) | TW201215603A (es) |
| WO (1) | WO2012001093A2 (es) |
| ZA (1) | ZA201208329B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109692153B (zh) * | 2017-10-24 | 2021-01-22 | 北京睿创康泰医药研究院有限公司 | 一种富马酸卢帕他定的水溶液制剂 |
| CN108904557A (zh) * | 2018-09-04 | 2018-11-30 | 广州君博医药科技有限公司 | 一种含富马酸卢帕他定的眼膏及其制备方法 |
| CN109535127B (zh) * | 2018-12-05 | 2020-10-16 | 杭州仟源保灵药业有限公司 | 富马酸卢帕他定衍生物、其制备方法及中间体和用途 |
| CN110123739A (zh) * | 2019-05-14 | 2019-08-16 | 扬子江药业集团江苏紫龙药业有限公司 | 一种富马酸卢帕他定前非离子体凝胶制剂及其制备方法 |
| CN110123756A (zh) * | 2019-05-14 | 2019-08-16 | 扬子江药业集团江苏紫龙药业有限公司 | 一种富马酸卢帕他定喷鼻剂及其制备方法 |
| CN111426771A (zh) * | 2020-04-21 | 2020-07-17 | 深圳市深大检测有限公司 | 一种食品甜蜜素的检测前处理方法 |
| CN112426404B (zh) * | 2020-10-29 | 2023-02-28 | 太阳升(亳州)生物医药科技有限公司 | 用于制备富马酸卢帕他定口服液的方法 |
| CN112315903A (zh) * | 2020-11-20 | 2021-02-05 | 北京华氏开元医药科技有限公司 | 一种富马酸卢帕他定口服溶液及其制备方法 |
| CN112494429B (zh) * | 2020-12-29 | 2022-07-26 | 北京华氏开元医药科技有限公司 | 一种富马酸卢帕他定纳米乳液及其制备方法与应用 |
| CN116983309A (zh) * | 2022-04-25 | 2023-11-03 | 北京阳光德美医药科技有限公司 | 一种难溶性的抗过敏类药物制剂及其制备方法 |
| CN115414322A (zh) * | 2022-07-05 | 2022-12-02 | 杭州民生药物研究院有限公司 | 一种富马酸卢帕他定口服液体制剂及其制备工艺 |
| CN120022237A (zh) * | 2025-04-22 | 2025-05-23 | 广州市桐晖药业有限公司 | 一种富马酸卢帕他定口服液及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2042421B1 (es) * | 1992-05-22 | 1994-08-01 | Uriach & Cia Sa J | Procedimiento para la obtencion de la 8-cloro-11-*1-*(5-metil-3-piridil)metil*-4-piperidiliden*-6,11-dihidro-5h-benzo*5,6*ciclohepta*1,2-b*piridina. |
| ES2087818B1 (es) | 1993-11-24 | 1997-03-16 | Uriach & Cia Sa J | 8-cloro-11-(1-((5-metil-3-piridil)metil)-4-piperidiliden)-6,11-dihidro-5h-benzo-(5,6)cicloheptal(1,2-b)piridina, fumarato. |
| MX2007015577A (es) * | 2005-06-09 | 2008-02-25 | Biolipox Ab | Metodo y composiciones para el tratamiento de trastornos inflamatorios. |
| CN101669926B (zh) | 2008-09-11 | 2011-07-06 | 广州达信生物技术有限公司 | 用于鼻腔给药的液体制剂及其制备方法 |
| CN101669901B (zh) | 2008-09-11 | 2012-04-04 | 广州达信生物技术有限公司 | 用于眼部给药的液体制剂及其制备方法 |
| CN101926762B (zh) * | 2010-08-27 | 2012-07-18 | 海昌隐形眼镜有限公司 | 富马酸卢帕他定滴眼液及其制备方法 |
-
2011
- 2011-06-30 SI SI201130013T patent/SI2402012T1/sl unknown
- 2011-06-30 PH PH1/2012/502260A patent/PH12012502260A1/en unknown
- 2011-06-30 ES ES11172101T patent/ES2401318T3/es active Active
- 2011-06-30 CN CN201180030947.1A patent/CN103108635B/zh not_active Ceased
- 2011-06-30 PL PL11172101T patent/PL2402012T3/pl unknown
- 2011-06-30 PT PT111721015T patent/PT2402012E/pt unknown
- 2011-06-30 EP EP11172101A patent/EP2402012B1/en active Active
- 2011-06-30 MY MYPI2012700945A patent/MY161101A/en unknown
- 2011-06-30 JP JP2013517291A patent/JP5475929B2/ja active Active
- 2011-06-30 CA CA2798028A patent/CA2798028A1/en not_active Abandoned
- 2011-06-30 SG SG2012090817A patent/SG186270A1/en unknown
- 2011-06-30 AR ARP110102329A patent/AR082049A1/es not_active Application Discontinuation
- 2011-06-30 MX MX2012013077A patent/MX2012013077A/es active IP Right Grant
- 2011-06-30 WO PCT/EP2011/060994 patent/WO2012001093A2/en not_active Ceased
- 2011-06-30 BR BR112012029009-6A patent/BR112012029009B1/pt active IP Right Grant
- 2011-06-30 TW TW100123106A patent/TW201215603A/zh unknown
- 2011-06-30 EA EA201291151A patent/EA201291151A1/ru unknown
-
2012
- 2012-11-06 ZA ZA2012/08329A patent/ZA201208329B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY161101A (en) | 2017-04-14 |
| PH12012502260A1 (en) | 2016-10-21 |
| EP2402012B1 (en) | 2012-12-19 |
| SI2402012T1 (sl) | 2013-03-29 |
| PT2402012E (pt) | 2013-02-25 |
| WO2012001093A3 (en) | 2012-04-12 |
| EA201291151A1 (ru) | 2013-05-30 |
| CN103108635A (zh) | 2013-05-15 |
| WO2012001093A2 (en) | 2012-01-05 |
| MX2012013077A (es) | 2013-03-05 |
| JP2013533248A (ja) | 2013-08-22 |
| ZA201208329B (en) | 2013-07-31 |
| CA2798028A1 (en) | 2012-01-05 |
| EP2402012A2 (en) | 2012-01-04 |
| BR112012029009B1 (pt) | 2019-07-09 |
| EP2402012A3 (en) | 2012-02-29 |
| CN103108635B (zh) | 2014-10-15 |
| ES2401318T3 (es) | 2013-04-18 |
| TW201215603A (en) | 2012-04-16 |
| JP5475929B2 (ja) | 2014-04-16 |
| SG186270A1 (en) | 2013-01-30 |
| BR112012029009A2 (pt) | 2017-08-08 |
| PL2402012T3 (pl) | 2013-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082049A1 (es) | Formulaciones liquidas de rupatadina fumarato | |
| MX2010010647A (es) | Proceso para preparar formulaciones de dabigatran para administracion oral. | |
| PE20080423A1 (es) | Formulaciones de flibanserina y metodo para fabricarlas | |
| EA201101671A1 (ru) | Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина | |
| NO20081889L (no) | Fast vaksine formulering | |
| AR087863A1 (es) | Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico | |
| GB0914287D0 (en) | Compositions | |
| RU2010139958A (ru) | Стабилизированная фармацевтическая композиция, cодержащая доцетаксель | |
| AR074541A1 (es) | Composiciones desinfectantes de plata naturales | |
| PE20050822A1 (es) | Derivados de florfenicol con mejor solubilidad en agua | |
| PH12014500240A1 (en) | Formulations of deoxycholic acid and salts thereof | |
| PH12017500136A1 (en) | Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof | |
| AR085273A1 (es) | Formulacion liquida libre de propelente que comprende una droga antimuscarinica | |
| AR078785A1 (es) | Formulaciones de bazedoxifeno con antioxidantes | |
| WO2014178789A9 (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients | |
| PE20061437A1 (es) | Composicion en emulsion que comprende derivados de cicloalqueno, estable en rango acido | |
| HRP20140676T1 (hr) | Formulacije deoksikolne kiseline i njezinih soli | |
| MX2010003594A (es) | Formas cristalinas de sal sodica de dmxaa. | |
| AR080054A1 (es) | Formulaciones antiparasitarias topicas | |
| JP5922609B2 (ja) | ２−アミノ−３−（４−ブロモベンゾイル）フェニル酢酸含有水性組成物 | |
| ATE525371T1 (de) | Salze von imidazol-5-carbonsäure-derivaten, herstellungsverfahren und verwendung davon | |
| NZ600577A (en) | Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof | |
| WO2017024953A1 (zh) | 尼莫地平水溶性衍生物及其制备方法和应用 | |
| PE20030092A1 (es) | Formulacion de una solucion de inhalacion con una sal de tiotropio | |
| EP1868613A4 (en) | POLYMORPHOS OF 3-O- (3 ', 3'-DIMETHYLSUCCINYL) BETULINIC DI-N-METHYL-D-GLUCAMINE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |